Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
VCEL
vs
S&P 500
VCEL
S&P 500
Over the past 12 months, VCEL has significantly outperformed S&P 500, delivering a return of +48% compared to S&P 500's +3% growth.
Stocks Performance
VCEL vs S&P 500
Performance Gap
VCEL vs S&P 500
Create a free account · No card needed
Performance By Year
VCEL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vericel Corp
Glance View
Vericel Corp makes and sells specialty cell-therapy products for difficult orthopedic and burn injuries. Its main products are used by surgeons and hospitals to treat damaged knee cartilage and severe burns, where standard treatments may not work as well. The company focuses on very specific medical problems instead of broad drug categories. Its customers are hospitals, operating rooms, orthopedic surgeons, and burn centers. Vericel earns money when these medical providers buy its approved therapies for use in patients, with payment often coming through the healthcare reimbursement system. In simple terms, it sells high-value, procedure-based treatments that are used in specialized care settings. What makes Vericel different is that it sits between drug makers and surgical care. It does not mass-market everyday medicines; it develops and manufactures living-cell products that are tied to a specific patient procedure and medical specialist. That gives it a focused role in regenerative medicine and makes its business closely linked to hospital and surgeon adoption rather than broad consumer demand.
Create a free account · No card needed